Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University , Nanjing , China.
Department of Biomedical Engineering, University of California , Davis, California.
Am J Physiol Heart Circ Physiol. 2019 Feb 1;316(2):H408-H420. doi: 10.1152/ajpheart.00411.2018. Epub 2018 Nov 21.
Increased expression of vascular cell adhesion molecule 1 (VCAM-1) on the aortic endothelium is an early marker of atherogenesis, promoted in part by elevated levels of inflammatory cytokines such as TNF-α. Mammalian target of rapamycin (mTOR) is a ubiquitous signaling molecule that has been considered to contribute to diverse cellular processes through mTOR complex 1 (mTORC1) or complex 2 (mTORC2). This study aimed to elucidate the role of mTOR signaling in TNF-α-induced VCAM-1 expression by the arterial endothelium. Primary human aortic endothelial cells (HAECs) were treated with low-dose (0.1 ng/ml) TNF-α, and VCAM-1 expression was measured by real-time quantitative PCR, Western blot analysis, and flow cytometry. Inhibition of mTOR through siRNA-mediated depletion or treatment with chemical inhibitors rapamycin or torin 1 suppressed VCAM1 transcription, which translated to inhibition of VCAM-1 surface expression by HAECs and concomitant decreased adhesion of monocytes. A promoter luciferase assay and chromatin immunoprecipitation indicated that mTOR regulated VCAM1 transcription through a mechanism involving transcription factor GATA6. Activation of PKC-α and an increase in miR-200a-3p expression, caused by mTOR inhibition but not disruption of mTORC1 or mTORC2 singly or together, decreased TNF-α-induced GATA6 expression and its enrichment at the VCAM1 promoter. In conclusion, mTOR inhibition activates PKC-α independently of disruption of mTORC1 and/or mTORC2, which challenges the conventional wisdom regarding mTOR signaling. Moreover, mTOR signals through transcriptional and posttranscriptional mechanisms to elicit maximal cytokine-induced endothelial inflammation that precedes atherosclerosis. NEW & NOTEWORTHY Both mammalian target of rapamycin (mTOR) complex 1 (mTORC1) and mTORC2 contribute to PKC-α activation in the human aortic endothelium. Inhibition of mTOR is not equivalent to disruption of mTORC1 and/or mTORC2 in affecting human aortic endothelial cell signaling. Specifically, inhibition of mTOR causes PKC-α activation and miR-200a-3p upregulation, which independently suppresses TNF-α-induced transcription factor GATA6 expression and subsequently inhibits VCAM-1 expression and monocytic cell adhesion onto the aortic endothelium.
血管细胞黏附分子 1(VCAM-1)在主动脉内皮细胞中的表达增加是动脉粥样硬化形成的早期标志物,部分原因是炎症细胞因子如 TNF-α水平升高。雷帕霉素靶蛋白(mTOR)是一种普遍存在的信号分子,它被认为通过 mTOR 复合物 1(mTORC1)或复合物 2(mTORC2)来促进多种细胞过程。本研究旨在阐明 mTOR 信号通路在 TNF-α诱导的动脉内皮 VCAM-1 表达中的作用。用低剂量(0.1ng/ml)TNF-α处理原代人主动脉内皮细胞(HAECs),通过实时定量 PCR、Western blot 分析和流式细胞术测量 VCAM-1 的表达。通过 siRNA 介导的耗竭或化学抑制剂雷帕霉素或 torin 1 抑制 mTOR,抑制 VCAM1 转录,进而抑制 HAECs 表面 VCAM-1 的表达,并伴有单核细胞黏附减少。启动子荧光素酶测定和染色质免疫沉淀表明,mTOR 通过涉及转录因子 GATA6 的机制调节 VCAM1 转录。PKC-α 的激活和 miR-200a-3p 表达的增加,是由 mTOR 抑制引起的,而不是破坏 mTORC1 或 mTORC2 单独或一起引起的,降低了 TNF-α诱导的 GATA6 表达及其在 VCAM1 启动子上的富集。总之,mTOR 抑制通过激活 PKC-α 而无需破坏 mTORC1 和/或 mTORC2 来激活,这对 mTOR 信号的传统观念提出了挑战。此外,mTOR 通过转录和转录后机制发出信号,引发动脉粥样硬化前的最大细胞因子诱导的内皮炎症。新的和值得注意的是,哺乳动物雷帕霉素靶蛋白(mTOR)复合物 1(mTORC1)和 mTORC2 都有助于人主动脉内皮细胞中 PKC-α 的激活。抑制 mTOR 与破坏 mTORC1 和/或 mTORC2 对人主动脉内皮细胞信号的影响并不等同。具体而言,抑制 mTOR 会引起 PKC-α 的激活和 miR-200a-3p 的上调,这会独立地抑制 TNF-α 诱导的转录因子 GATA6 表达,进而抑制 VCAM-1 的表达和单核细胞黏附到主动脉内皮细胞上。